Prior to founding Amolyt Pharma, Thierry Abribat had founded and managed Alizé Pharma 2, that was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and Alizé Pharma, that was acquired by Millendo Therapeutics (Nasdaq: MLND). Prior to his biotech entrepreneur track, he had held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TSX: TH) and at OPi, Pharmaceuticals for Rare Diseases, until OPi’s acquisition by EUSA Pharma Inc. Thierry began his career as a scientist for Sanofi, then at University of Montreal and as a consultant to the biopharmaceutical industry. He holds a Doctorate of Veterinary Medicine and a Ph.D. from the National Polytechnic Institute of Toulouse, France.

Recent Milestones:
Jan 2023: closing of a 130M€ Series C financing
 May 2023: launch of a Phase 3 trial of eneboparatide for hypoparathyroidism
June 2023: launch of a Phase 1 trial of AZP-3813 for acromegaly
Nov 2023: Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Upcoming Milestones:
H1 2024: topline results from the Phase 1 clinical trial of AZP-3813 for acromegaly
H1 2025: topline results from the Phase 3 clinical trial of eneboparatide for hypoparathyroidism Products: Eneboparatide (AZP-3601), a parathyroid hormone analog for the potential treatment of hypoparathyroidism AZP-3813, a Growth Hormone Receptor antagonist for the potential treatment of acromegaly

Investors: Novo Holdings; EQT Life Sciences; Andera Partners; Kurma Partners; Sofinnova Partners; ICG; Innobio 2 (Bpifrance); MGB Ventures; Pontifax; Orbimed; Sectoral Asset Management; Tekla; CTA Life Sciences

Full Company address & contact details: Amolyt Pharma, 15 chemin du Saquin, 69130 Ecully, France contact@amolyt.com